FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3149071734> ?p ?o ?g. }

• W3149071734 endingPage "120791" @default.
• W3149071734 startingPage "120791" @default.
• W3149071734 abstract "The effective chemotherapeutic drug, doxorubicin (DOX), elicits immunogenic cell death (ICD) and additional anticancer immune responses during chemotherapy. However, it also induces severe side effects and systemic immunosuppression, hampering its wide clinical application. Herein, we constructed cancer-activated DOX prodrug by conjugating the cathepsin B-cleavable peptide (Phe-Arg-Arg-Gly, FRRG) to a doxorubicin (DOX), resulting in FRRG-DOX that self-assembled into cancer-activated DOX prodrug nanoparticles (CAP-NPs). The resulting CAP-NPs were further stabilized with the FDA-approved compound, Pluronic F68. CAP-NPs formed stable prodrug nanoparticles and they were specifically cleaved to cytotoxic DOX molecules only in cathepsin B-overexpressing cancer cells, inducing a cancer cell-specific cytotoxicity. In particular, the CAP-NPs induced ICD through cathepsin B-cleavage mechanism only in targeted cancer cells in vitro. In colon tumor-bearing mice, selectively accumulated CAP-NPs at tumors enhanced antitumor immunity without DOX-related severe toxicity, inflammatory response and systemic immunosuppression. Moreover, cytotoxicity against immune cells infiltrated into tumor microenvironment was significantly reduced compared to free DOX, leading to increased response to checkpoint inhibitor immunotherapy. The combinatorial treatment of CAP-NPs with anti-PD-L1 exhibited high rate of complete tumor regression (50%) compared to free DOX with anti-PD-L1. Concurrently, DOX-related side effects were greatly reduced during chemoimmunotherapy. Collectively, our results suggest that cancer-activated DOX prodrug nanoparticles provide a promising approach to increase clinical benefit by inducing an immune response preferentially only to targeted cancer cells, not to normal cells and immune cells, and potentiates checkpoint inhibitor immunotherapy." @default.
• W3149071734 created "2021-04-13" @default.
• W3149071734 creator A5004353244 @default.
• W3149071734 creator A5027987738 @default.
• W3149071734 creator A5029305363 @default.
• W3149071734 creator A5029505798 @default.
• W3149071734 creator A5030603383 @default.
• W3149071734 creator A5042165953 @default.
• W3149071734 creator A5043658693 @default.
• W3149071734 creator A5052855198 @default.
• W3149071734 creator A5055447223 @default.
• W3149071734 creator A5065286478 @default.
• W3149071734 creator A5073676165 @default.
• W3149071734 creator A5088015757 @default.
• W3149071734 creator A5088717584 @default.
• W3149071734 creator A5090601755 @default.
• W3149071734 date "2021-05-01" @default.
• W3149071734 modified "2023-10-16" @default.
• W3149071734 title "Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity" @default.
• W3149071734 cites W1969604041 @default.
• W3149071734 cites W1973008499 @default.
• W3149071734 cites W1976041621 @default.
• W3149071734 cites W1980832510 @default.
• W3149071734 cites W1990859382 @default.
• W3149071734 cites W2003593390 @default.
• W3149071734 cites W2008119200 @default.
• W3149071734 cites W2038439210 @default.
• W3149071734 cites W2041278387 @default.
• W3149071734 cites W2047311244 @default.
• W3149071734 cites W2058493200 @default.
• W3149071734 cites W2064844509 @default.
• W3149071734 cites W2084949476 @default.
• W3149071734 cites W2085504000 @default.
• W3149071734 cites W2093424661 @default.
• W3149071734 cites W2098378066 @default.
• W3149071734 cites W2100326315 @default.
• W3149071734 cites W2128779315 @default.
• W3149071734 cites W2133528707 @default.
• W3149071734 cites W2170452186 @default.
• W3149071734 cites W2315635540 @default.
• W3149071734 cites W2344644350 @default.
• W3149071734 cites W2344850880 @default.
• W3149071734 cites W2436942341 @default.
• W3149071734 cites W2524574476 @default.
• W3149071734 cites W2536814636 @default.
• W3149071734 cites W2563647161 @default.
• W3149071734 cites W2622319425 @default.
• W3149071734 cites W2790899814 @default.
• W3149071734 cites W2802126705 @default.
• W3149071734 cites W2883164386 @default.
• W3149071734 cites W2903686952 @default.
• W3149071734 cites W2904107490 @default.
• W3149071734 cites W2906932524 @default.
• W3149071734 cites W2951862601 @default.
• W3149071734 cites W2972201698 @default.
• W3149071734 cites W2972396835 @default.
• W3149071734 cites W2982371398 @default.
• W3149071734 cites W3006930853 @default.
• W3149071734 cites W3045408055 @default.
• W3149071734 cites W3097856296 @default.
• W3149071734 doi "https://doi.org/10.1016/j.biomaterials.2021.120791" @default.
• W3149071734 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33831739" @default.
• W3149071734 hasPublicationYear "2021" @default.
• W3149071734 type Work @default.
• W3149071734 sameAs 3149071734 @default.
• W3149071734 citedByCount "70" @default.
• W3149071734 countsByYear W31490717342021 @default.
• W3149071734 countsByYear W31490717342022 @default.
• W3149071734 countsByYear W31490717342023 @default.
• W3149071734 crossrefType "journal-article" @default.
• W3149071734 hasAuthorship W3149071734A5004353244 @default.
• W3149071734 hasAuthorship W3149071734A5027987738 @default.
• W3149071734 hasAuthorship W3149071734A5029305363 @default.
• W3149071734 hasAuthorship W3149071734A5029505798 @default.
• W3149071734 hasAuthorship W3149071734A5030603383 @default.
• W3149071734 hasAuthorship W3149071734A5042165953 @default.
• W3149071734 hasAuthorship W3149071734A5043658693 @default.
• W3149071734 hasAuthorship W3149071734A5052855198 @default.
• W3149071734 hasAuthorship W3149071734A5055447223 @default.
• W3149071734 hasAuthorship W3149071734A5065286478 @default.
• W3149071734 hasAuthorship W3149071734A5073676165 @default.
• W3149071734 hasAuthorship W3149071734A5088015757 @default.
• W3149071734 hasAuthorship W3149071734A5088717584 @default.
• W3149071734 hasAuthorship W3149071734A5090601755 @default.
• W3149071734 hasConcept C108215921 @default.
• W3149071734 hasConcept C109316439 @default.
• W3149071734 hasConcept C121608353 @default.
• W3149071734 hasConcept C126322002 @default.
• W3149071734 hasConcept C154317977 @default.
• W3149071734 hasConcept C185592680 @default.
• W3149071734 hasConcept C202751555 @default.
• W3149071734 hasConcept C203014093 @default.
• W3149071734 hasConcept C2776107976 @default.
• W3149071734 hasConcept C2776694085 @default.
• W3149071734 hasConcept C2777701055 @default.
• W3149071734 hasConcept C2777877232 @default.
• W3149071734 hasConcept C2780790343 @default.
• W3149071734 hasConcept C2781303535 @default.

• next